Received: 12 August 2021
Accepted: 15 March 2022
First Online: 23 April 2022
: Ethics approval for all experimental protocols was obtained from the Alfred Hospital Human Research Ethics Committee (HREC 149/19).Informed consent was obtained from all participants.All methods were carried out in accordance with relevant guidelines and regulations.
: Consent for publication was obtained from all study participants.
: JH has received speaker fees and investigator-initiated grants from Gilead Sciences. JD reports funding to his institution for investigator-initiated research from Gilead Sciences and Abbvie; and consultancies from Gilead Sciences and Abbvie. MH receives funding from Gilead Sciences and Abbvie for investigator-initiated research. AT has received consulting fees from Gilead, Abbvie, Roche, BMS, Merck, Immunocore, Janssen, Assembly Biosciences, Arbutus, Eisai, Ipsen and Bayer, speaker fees from Gilead Sciences, and investigator-initiated grants from Gilead Sciences. Burnet Institute acknowledges support from the Victorian Government Operational Infrastructure Fund.